Tinlarebant

Stargardt disease type 1 causes progressive loss of central vision. A Netherlands registry estimated annual incidence at 1.67–1.95 per million and 2018 prevalence at approximately 1 in 22,000–19,000. These estimates should not be treated as equivalent to the sponsor’s estimate of 53,000 affected people in the United States. A Brazilian study compared 41 participants with Stargardt disease with 46 healthy volunteers and reported impaired vision-specific quality of life and functional vision.

DRAGON randomized 104 participants, with 69 assigned to tinlarebant and 35 to placebo. In the modified full analysis set of 96 participants, annual DDAF lesion growth was 0.38 versus 0.59 mm²/year, a reported reduction of 35.7% with P = 0.0033. Visual-acuity change was minimal in both groups over 24 months. Ocular treatment-emergent adverse events occurred in 53 of 69 participants (76.8%) receiving tinlarebant and 8 of 35 (22.9%) receiving placebo. Four tinlarebant recipients (5.8%) discontinued study drug because of ocular adverse events.

The reported phase 3 benefit concerns slower retinal lesion growth, not a demonstrated between-group improvement in visual acuity over 24 months. FDA acceptance with Priority Review and a February 12, 2027 target action date represents an application under review, not marketing approval. The sponsor’s March 2027 launch timing remains a forecast.